PHILADELPHIA, December 17, 2015 — Premier Research announces the appointment of Paul Hallenbeck as Executive Director for Oncology. Dr. Hallenbeck has more than 20 years of experience in the biotech industry and expertise in all phases of oncology drug discovery, development, and commercialization, including work in complex, targeted biologics.

Dr. Hallenbeck most recently served as Chief Scientific Officer for oncology therapeutics specialist Hangzhou Bensheng Pharmaceuticals. Prior to that, he founded Synbody Biotechnology Inc., serving as the company’s President and CEO and leading development of antibody-like technologies and compounds — discovering and improving compounds directed at cancer targets previously believed to be undruggable.

He was Chief Scientific Officer at Neotropix Inc., an oncology therapeutics company, and began his career at Novartis, advancing to senior fellow and program head.

Dr. Hallenbeck holds a doctorate in microbiology from the University of Illinois and a bachelor’s degree in chemistry from Siena College.

About Premier Research

Premier Research is a leading contract research organization serving the needs of biotechnology, pharmaceutical and medical device companies worldwide. The company has a wealth of experience in the execution of global, regional, and local clinical development programs with a special focus on addressing unmet needs in such areas as analgesia, CNS, rare diseases, medical device and diagnostics, and pediatric research. Premier Research operates in 84 countries and employs more than 1,000 professionals, including a strong international network of clinical monitors and project managers, regulatory, data management, statistical, scientific, and medical experts. With its mission to improve productivity in clinical development, the company aligns itself with the mission of its customers to bring new medical treatments to patients promptly, accurately, and cost-effectively.